Cargando…
Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
PURPOSE: To evaluate the safety and efficacy of favipiravir, which is prescribed for the treatment of patients with mild-to-moderate coronavirus disease 2019 (COVID-19) in India. PATIENTS AND METHODS: This was a prospective, open-label, multicenter, single-arm postmarketing study conducted in India....
Autores principales: | Reddy, Pavan Kumar, Patil, Saiprasad, Khobragade, Akash, Balki, Akash, Raj, Aneesh, Kalikar, Mrunalini, Reddy, Raghavendra, Shinde, Ravindra, CR, Jayanthi, Mutha, Abhinandan, Boyilla, Nagaraju, Rajadhyaksha, Girish C, Karnik, Niteen, Bhagat, Sagar, Pendse, Amol, Dhage, Priyanka, Wu, Wen, Rangwala, Shabbir, Barkate, Hanmant |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9078344/ https://www.ncbi.nlm.nih.gov/pubmed/35535140 http://dx.doi.org/10.2147/IJGM.S349241 |
Ejemplares similares
-
Efficacy and safety of single-inhaler triple therapy of glycopyrronium, formoterol and fluticasone in patients with COPD: a double-blind, randomised controlled trial
por: Salvi, Sundeep, et al.
Publicado: (2021) -
Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: A randomized, comparative, open-label, multicenter, phase 3 clinical trial
por: Udwadia, Zarir F., et al.
Publicado: (2021) -
Real-World Experience with Favipiravir for the Treatment of Mild-to-Moderate COVID-19 in India
por: Joshi, Shashank, et al.
Publicado: (2022) -
Comparative efficacy and safety of glycopyrronium/formoterol fixed-dose combination versus glycopyrronium monotherapy in patients with moderate-to–severe COPD
por: Salvi, Sundeep, et al.
Publicado: (2022) -
Role of favipiravir in the treatment of COVID-19
por: Joshi, Shashank, et al.
Publicado: (2021)